Here are 6 of the best results this ASX reporting season (so far), and 6 of the worst!

This article recaps some of the best results this ASX reporting season so far, as well as some of the worst – 6 of each to be exact.

We are looking not so much at the highest profits or losses but perhaps the most extreme reactions and whether or not the results were an unexpected outperformance or flop relative to what had been anticipated. Moreover, this not intended to be an exhaustive list, some may notice omissions such as Guzman y Gomez – we excluded it because it was obvious it would fall unless it reported stellar revenue and profit growth as opposed to just average growth.

With that out of the way, here are 6 of the best and 6 of the worst.

What are the Best ASX stocks to invest in right now?

Check our buy/sell tips

6 of the best results this ASX reporting season (so far)

QBE (ASX:QBE)

The corporate-focused insurer posted a strong full-year 2025 result with statutory net profit up about 21% to roughly US$2.15bn and net insurance revenue rising to about US$18.4bn. The company also lifted its dividend by about 25% and improved its combined operating ratio, underpinning solid underwriting performance.

The outlook remained constructive with guidance for mid‑single‑digit premium growth and a stable underwriting margin, supporting confidence in continued earnings resilience. QBE’s share price traded >6% higher on the day of the result, reflecting confidence in continued mid-single-digit premium growth and a constructive outlook for FY26.

Hub24 (ASX:HUB)

Hub24 delivered a standout half-year to December 31 2025 with revenue up around 26% to ~$246m, underlying NPAT up roughly 60%, record platform net inflows of ~$10.7bn and an upgraded FY27 FUA target.

The company is a super platform business and it is benefiting from a flight of older, more affluent members to the platform who are now paying more attention to their retirement savings – at the expense of older super funds. The stock rallied nearly 20% at market open and closed up double-digit percentages as investors rewarded strong growth and margin expansion.

JB Hi-Fi (ASX:JBH)

Australia’s best known electronics retailers reported H1 FY26 revenue of about $6.1 billion and profit after tax of ~$305.8 million, beating forecasts and supporting a notably higher interim dividend.

Its shares jumped by as much as 15% on the release as the results supported resilience in consumer demand – despite softer January trading, Black Friday and Boxing Day were strong. There is also speculation by investors that it could be a way to play the AI boom, without the high capex.

NAB (ASX:NAB)

NAB impressed with a robust first-quarter trading update, with cash earnings up around 16% to over $2 billion and net profit rising strongly, helping shares hit a record high and reflecting a solid earnings trajectory and supportive net interest margin of 1.8%. Business loan volumes climbed about 7% and housing loans ~5%, while expenses were broadly flat and credit quality remained stable. Market confidence was also lifted by management’s commentary on sustainable growth and solid balance‑sheet metrics, underpinning a constructive outlook for FY26 earnings.

It was not the only bank to report a mega profit and it was outdone by CBA, but investors were impressed because it hasn’t been the easiest time since Andrew Irvine took over. He made headlines this week, but only for telling us what we already know – that our economy needs microeconomic reform if we want any genuine rise in living standards.

Sonic Healthcare (ASX:SHL)

Sonic reported revenue up about 17% to A$5.45bn and net profit up about 11% to A$262m, with EBITDA rising roughly 10% and EPS to about 53.1 cents per share. The board also lifted the interim dividend to 45 cents (60% franked) while reaffirming full‑year EBITDA guidance in the range of A$1.87–1.95bn, signalling management’s confidence in execution across its global business.

Underlying the strong response is Sonic’s diversified global diagnostics franchise and improving operational performance with solid organic revenue growth in pathology and radiology, strategic acquisitions integrating well and disciplined cost control supporting margin resilience.

Superloop (ASX:SLC)

In the half‑year to 31 December 2025, Superloop reported revenue of A$318.6m, up from ~A$258m a year earlier, and returned to profitability with a net profit of approximately A$5.1m, reversing losses from prior periods and signalling improved operational momentum.

A key catalyst for both the result and investor optimism was Superloop’s strategic acquisition of Lightning Broadband, which expands its footprint and customer base, while underlying core operations delivered stronger sales. This combination of returning to profit, revenue growth, and successful strategic execution has bolstered confidence in Superloop’s growth outlook, with analysts and investors now focusing on continued profitability expansion, customer retention, and integration synergies.

6 of the worst results this ASX reporting season (so far)

Inghams (ASX:ING)

Inghams saw its first‑half profit tumble sharply as costs, excess inventory and supply chain shifts hit the bottom line. 1H FY26 NPAT plunged about 65% to A$18.1m, underlying EBITDA fell ~35% to A$80.6m, and the company cut full‑year EBITDA guidance while trimming the interim dividend to 4¢ (from 11¢), missing expectations.

The heavy profit slump and weaker outlook triggered selling as margins were squeezed and future growth looked cloudy.

Zip (ASX:ZIP)

The BNPL provider reported strong headline growth — HY26 revenue rose to about A$658m and net profit surged ~128% to A$52‑66m — but the share price crashed around 30‑38%. Investors focused on flat second‑half earnings guidance, slipping revenue margins in ANZ, softer customer adds, and pressure on profitability expectations that signal slowing momentum ahead.

Perhaps investors are just ‘risk-off’ now that interest rates are headed back up, even if it may be a catalyst for momentum. After all, one of Zip’s selling points is that it provides finance without interest.

Reliance Worldwide (ASX:RWC)

The plumbing equipment provided continued to be plagued by US tariffs, supply chain issues and rising interest rate subduing demand. Interim (i.e. half-yearly) sales dropped ~4.6% to US$645.4m and net profit fell ~35% to US$43.7m as US tariffs and weak demand in key markets hit margins; adjusted EBITDA was down ~22% to US$111m, prompting a share slide of around 6‑9% on disappointment with both growth and regional performance.

CSL (ASX:CSL)

It was a looming sign that the CEO, ultimately the shortest serving since privatisation, left within hours of the result being released. The biotech giant, delivered a softer result with first‑half revenue declining about 4% to ~US$8.3bn and underlying NPATA down roughly 7%, missing sky‑high market expectations.

Even though it held full‑year guidance, the combination of slowing top‑line, margin pressure, the leadership change and uncertainty over the future saw the share retreat sharply on its results. The reality is that if nothing else, it has lost its reputation and it is far harder to repair than to destroy it. It is being hit by anti vaccination sentiment in the US, it has not seen the return on Vifor to justify the huge price tag and innovation has been slower.

Treasury Wines Estates (ASX:TWE)

TWE swung to a large half‑year loss of around A$649m after a significant impairment on US assets, with revenue down about 17% to ~A$1.3bn and operating income down ~40%. The company also suspended its dividend to preserve cash amid weakening demand in China and the US, leading investors to offload stock amid questions over its recovery path.

Investors thought a difficult few years were behind it once China finally got rid of its tariffs. But whether or tariffs or not, that does not aid consumer sentiment in China nor undo the damage of years of competing companies gain a foothold in the market.

Pro Medicus (ASX:PME)

Pro Medicus, the provider of the Visage radiology software, reported solid growth — 1H FY26 revenue up ~28% to ~A$124.8m and NPAT up ~30% to ~A$67.3m — but its share plunged as results were seen as “not strong enough” against high expectations, and negative sentiment toward premium tech/healthcare valuations likely exacerbated selling, outweighing earnings growth.

For so long it kept growing because it kept signing long-term contracts worth millions whilst still claiming to have only penetrated a fraction of the market. There was hype it could benefit from the AI boom. It was always trading at very high P/E multiples but investors shrugged it off…until the RBA reversed course and started hiking rates again.